Spanish Blood Cancer Library - What are the risks and benefits of Ibrutinib and Idelalisib?

dbrock's picture
¿Cuáles son los riesgos y beneficios de ibrutinib y de idelalisib? ¿Cómo manejamos los efectos secundarios de los nuevos inhibidores de la tirosina cinasa?
Marco A. Ruiz, MD, GRACE Faculty
For this video on the risks and benefits of Ibrutinib Idelalisib, GRACE sat down with Marco Ruiz, MD, an oncologist at Memorial Cancer Institute specializing in hematologic or blood cancers, including leukemia, lymphoma, myelodysplastic syndrome (MDS) and myelofibrosis. He is also an experienced bone marrow transplant specialist and is active in cancer research.

 

In this series Ibrutinib Idelalisib, Dr. Ruiz shares information regarding Chronic Lymphocytic Leukemia & Non-Hodgkin Lymphoma, (Leucemia crónica linfocítica y linfoma no Hodgkin).   This video discusses "What are the risks and benefits of Ibrutinib and Idelalisib? How do you manage the side effects of the new kinase inhibitors?"  (¿Cuáles son los riesgos y beneficios de ibrutinib y de idelalisib? ¿Cómo manejamos los efectos secundarios de los nuevos inhibidores de la tirosina cinasa?)


 

We would like to thank the following company for their support of this program:

 


 

Video Language: 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation